Kessler team receives funding to study factors leading to osteoarthritis after knee injury
Gerard Malanga, MD, and Nathan Hogaboom, PhD, of Kessler Foundation received a $185,707 award from The Geneva Foundation (Geneva) to study factors contributing to the development of osteoarthritis following acute knee injuries, a common disabling condition among active-duty military personnel.
The funding supports Kessler Foundation s participation as a collaborative partner in Musculoskeletal Injury and Rehabilitation Research for Operational Readiness (MIRROR) headquartered at the Uniformed Services University (USU).
The MIRROR program is managed by Geneva on behalf of USU. MIRROR supports a broad scope of musculoskeletal projects, including this two-year study entitled, MIRROR Collaboration: Chemical and cellular characterization of hemarthroses after traumatic knee injuries in active-duty military personnel.
Zoetis Inc.: Zoetis Receives European Commission Marketing Authorization for Solensia (frunevetmab), a New Therapy for Feline Osteoarthritis Pain
Solensia works as a monthly treatment targeting Nerve Growth Factor (NGF), a key player in OA pain
European Commission Marketing Authorization for a similar product in dogs, Librela
,
was received in November 2020 Zoetis Inc. (NYSE:ZTS) today announced that the European Commission has granted the marketing authorization for Solensia (frunevetmab), a new feline osteoarthritis treatment to alleviate pain. Osteoarthritis in cats is a very prevalent condition
1, existing in 40% of cats, and may generate pain and limit a cat s comfort and quality of life if not treated.
email article
Telephone-based cognitive behavioral therapy for insomnia (CBT-I) was effective in older adults with osteoarthritis pain, the randomized OATS trial showed.
Insomnia Severity Index (ISI) scores dropped by 8.1 points on the 28-point scale by 2 months after the intervention compared with a decrease of 4.8 points among controls who got an equal amount of education-only contact (
P 0.001).
A 3.0-point difference was maintained at 12-month follow-up (
P 0.001), Susan McCurry, PhD, of the University of Washington in Seattle, and colleagues reported in Results support provision of telephone CBT-I as an accessible, individualized, effective, and scalable insomnia treatment, the group concluded, calling the benefits large, robust, and sustained.
ARTHRITIS is a common condition that causes pain and inflammation in a joint. One of the most common types of arthritis is osteoarthritis. Taking curcumin has been shown to treat osteoarthritis.
Technavio Research: COVID-19 Impacts and Recovery | Osteoarthritis Therapeutics Market Research 2020-2024 | Technavio
Technavio has been monitoring the osteoarthritis therapeutics market and it is poised to grow by USD 2.99 billion during 2020-2024, progressing at a CAGR of almost 9% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment.
Click Get a Free sample report in minutes
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210203006018/en/
Technavio has announced its latest market research report titled Global Osteoarthritis Therapeutics Market 2020-2024 (Graphic: Business Wire)